On Monday, April 25, 2022, the U.S. Food and Drug Administration (FDA) granted approval for the COVID-19 drug remdesivir (aka Veklury) for the treatment of children under 12.  The approval covers children 28 days and older who weigh at least 3 kilograms or over 6 1/2 pounds and are either hospitalized or at high-risk of severe illness. The FDA also emphasized that remdesivir is not a replacement for vaccination.

Previously, remdesivir was under emergency use authorization for children. There is still no authorized vaccine for children under 5-years-old. 

Remdesivir had already been approved as a treatment for adults. 

To read more from The Hill, click here.